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The aim of our study was to evaluate, through the Eurocord and
European Group for Blood and Marrow Transplantation (EBMT)
registries, outcomes and risk factors for outcomes in adult
patients who underwent single or double unrelated cord blood
transplantation (UCBT) for myelodysplastic syndrome (MDS)
or secondary acute myeloblastic leukemia (sAML). A total of
180 adults with MDS (n¼39) or sAML (n¼ 69) were analyzed.
Risk factors for outcomes were analyzed using the Fine and
Gray method and the Cox model. Median age was 43 (18–72)
years. In all, 77 patients (71%) received a single UCBT.
Myeloablative conditioning regimen (MAC) was given to 57
(53%) patients. Median numbers of nucleated and CD34þ cells
at freezing were 3.6107 and 1.1 105 kg. At 60 days, cumu-
lative incidence of neutrophil recovery was 78±4% and was
independently associated with the number of CD34þ cells per
kg (41.1105; P¼0.005) and advanced disease status (blasts
o5% at time of UCBT, P¼0.016). A 2-year non-relapse mortality
(NRM) was significantly higher after MAC (62 vs 34%; P¼0.009).
A 2-year disease-free-survival (DFS) and overall survival (OS)
were 30 and 34%, respectively. In multivariate analysis, patients
with high-risk disease (blasts 45% and International Prognos-
tic scoring system (IPSS) intermediate-2 or high in MDS) had
significant poorer DFS (hazard ratio (HR): 1.76; P¼0.047). In
spite of high NRM, these data indicate that UCBT is an
acceptable alternative option to treat adults with high-risk
MDS or sAML, without a suitable human leukocyte antigen
(HLA)-matched donor.
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Introduction
Since the publication of encouraging results with unrelated
cord blood transplantation (UCBT) in early 2000, this procedure
has been used with increasing frequency in patients lacking
an human leukocyte antigen (HLA)-matched donor.1–3 The main
advantages of UCBT include rapidity of availability and
the possibility of using partially HLA-mismatched UCB units
without high risk of graft vs host disease (GVHD). The limiting
factor is an engraftment rate of around 70–90%, which is highly
influenced by total nucleated and CD34þ cell dose at UCB
collection.4 To overcome this obstacle, double UCBT has been
successfully performed.5 UCBT, initially reserved to children,
has been more frequently used in adults because of the use
of double UCBT.6 For patients with acute leukemia, UCBT is
currently accepted as an alternative source in patients lacking
HLA-matched unrelated donor. In contrast, up to now, few data
exist for patients with myelodysplastic syndrome (MDS). Patients
with MDS or secondary acute myeloblastic leukemia (sAML)
respond very poorly to chemotherapy and in higher risk patients,
survival is below 10% at 2 years.7–9 New medications such as
demethylating agents have shown some hematological and
survival improvements,10–13 but allogeneic hematopoietic stem
cell transplantation (HSCT) remains indicated in high-risk
patients aged o60 years.14–16 Unfortunately, only 40–50%
of patients will have a suitable HLA-matched donor. UCBT has
been used as an alternative for some patients lacking an adult
donor. The aim of this study was to evaluate outcomes of adult
patients reported to the Eurocord and European Group for Blood
and Marrow Transplantation (EBMT) registries, who received
single or double UCBT for MDS or sAML.
Materials and methods
Data collection and population
Eurocord is an International registry operating on behalf of the
European Blood and Marrow Transplant (EBMT). Participation in
this study was open to European and non-European centers
performing UCBT. The median number of patients reported by
each center was 1 (range: 1–16). A total of 27 patients have been
previously published.17 The study included all consecutive
patients receiving UCBT between January 1997 and December
2008, who were 18 years old or more and were diagnosed with
MDS or sAML at time of transplantation. Patients with AML
secondary to MDS or therapy-related leukemia were included
because their prognoses are usually considered similar. Patients
who had received previous allogeneic hematopoietic stem cell
transplant (HSCT) or a manipulated (ex vivo expansion) UCBT
were excluded. Data regarding patient, disease and transplant
characteristics and clinical outcomes were collected by
Received 6 April 2010; revised 29 June 2010; accepted 16 July 2010;
published online 30 September 2010
Correspondence: Dr M Robin, Service d’he´matologie-greffe, Hoˆpital
Saint-Louis, APHP, 1 avenue Claude Vellefaux, Paris 75475, Cedex
10, France.
E-mail: marie.robin@sls.aphp.fr
Leukemia (2011) 25, 75–81
& 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11
www.nature.com/leu
standardized questionnaire for each UCBT recipient. For MDS,
the questionnaire included MDS characteristics not only at
diagnosis and at the time of UCBT, but also at worst status.
A total of 108 patients met the above eligibility criteria.
Definitions
MDS and AML were classified according World Health Organiza-
tion criteria. Patients with chronic myelomonocytic leukemia
were also included in the study. The possible diagnoses for
patients were: refractory anemia with or without ringed side-
roblast, refractory cytopenias with multilineage dysplasia with or
without ringed sideroblasts, refractory anemia with excess of blasts
1 (5–10%) and 2 (11–19%), unclassifiable MDS, MDS associated
with isolated 5q, chronic myelomonocytic leukemia and AML.
Classification and calculation of International Prognostic scoring
system (IPSS) were performed at the time of diagnosis, worse
status and transplantation. Cytogenetic classification was defined
according to the Medical Research Council classification for
AML18 and the IPSS score for MDS.19 Secondary acute leukemia
was either transformed from MDS or therapy-related AML. At the
time of UCBT, patients were classified as having high-risk disease
if they had AML not in first or second remission or MDS with
intermediate-2 or high IPSS score and disease with 45% blasts
in bone marrow. Worst status of MDS was defined as either
transformation into AML or the highest documented bone marrow
blast count between diagnosis and UCBT. Donor–recipient HLA
compatibility was determined by serology level typing for HLA-A
and -B and by high-resolution allele level typing for HLA-DRB1.
Transplants were classified as HLA mismatched with 1, 2, 3 or
4 differences if disparities were detected in HLA-A, -B or -DRB1.
The date of neutrophil engraftment was defined as the first of
3 consecutive days with neutrophil counts40.5 109/l. Platelet
engraftment was defined as the first of 7 consecutive days with
platelet counts 420 109/l without transfusion. Primary graft
failure was diagnosed when the neutrophil engraftment end
point was not reached by day 60 or when a second transplant
for non-engraftment was performed.
Determination of the comorbidity score was assigned using
an HSCT-specific comorbidity index.20
GVHD was diagnosed and graded according to standard
criteria.21,22
Relapse was defined on the basis of morphological evidence of
MDS or AML in bone marrow or in tissue or organ (chloroma).
Statistical analysis
The end points were engraftment, acute GVHD (aGVHD),
relapse, overall survival (OS), event-free survival and non-
relapse mortality (NRM). All time-to-event data were calculated
from the date of transplantation to the date of the event or last
follow-up, whichever occurred first. NRM was defined as death
without relapse and was analyzed in a competing risk setting,
with relapse being treated as the competing event. Engraftment
and acute and chronic GVHD were also analyzed in a
competing risk setting, with death as competing events.
The cumulative incidences (CIs) of engraftment, acute and/or
chronic GVHD, relapse and NRM were estimated using the Gray
method. The probabilities of OS and event-free survival were
estimated using the Kaplan–Meier method.23 Covariates consi-
dered were age, diagnosis at the time of UCBT (MDS, AML),
disease risk (high risk, low risk), period of transplant (1998–2005
vs 2006–2008), recipient cytomegalovirus serostatus, median
number of nucleated cells infused, conditioning regimen (reduced
intensity conditioning regimen (RIC) or myeloablative condition-
ing regimen (MAC)), recipient gender, GVHD prophylaxis
(cyclosporine plus steroids vs cyclosporine plus mycophenolate),
use of antithymoglobulin before UCBT, number of UCB units
(single vs double), median time from diagnosis to UCBT, HLA
disparity, number of total nucleated and CD34þ cells collected
and infused. Multivariate models for outcomes were performed
using the Fine and Gray method24 for engraftment, acute and
chronic GVHD, relapse and NRM and using the Cox model25
for OS and DFS. Multivariate models were constructed using a
forward selection procedure and only variables that attained
a P-value p0.10 in univariate analysis were entered in the final
model. All tests were two-sided. Statistical analyses were
performed with SPSS 15.0 statistical software (SPSS, Chicago, IL,
USA), Splus 6.1 (MathSoft, Seattle, WA, USA).
Results
Patient, disease and donor characteristics
Median patient age was 45 years (range, 18–72); 45 (42%) were
men and 74 (69%) had positive cytomegalovirus serology before
transplantation. Disease characteristics are shown in Table 1.
Table 1 Disease characteristics
Disease characteristics
Number of patients 108
Characteristics at diagnosis
WHO classification
RA or RCMD ± SR 16
RAEB1 19
RAEB2 31
Chronic myelomonocytic leukemia 10
Myelodysplasia unclassified or unknown 7
Therapy-related acute myeloid leukemia 25
Cytogenetics
Myelodysplasia 83
Favorable, no. (%) 28 (34)
Intermediate, no. (%) 18 (22)
Poor, no. (%) 25 (30)
Missing or incomplete, no. (%) 12 (14)
Therapy-related acute myeloid leukemia 25
Favorable, no. (%) 1 (4)
Intermediate, no. (%) 15 (60)
Poor, no. (%) 6 (24)
Missing or incomplete, no. (%) 3 (12)
Evolution from diagnosis to transplantation
Myelodysplasia transformed into AML, no. (%) 44 (53)
t-AML achieving first complete remission, no. (%) 18 (72)
Time from diagnosis to transplantation, months (range) 9 (2–158)
Status at the time of transplantation
All patients
Bone marrow blasts o5%, no. (%) 58 (54%)
Missing, no. (%) 8 (7%)
t-AML and myelodysplasia transformed into AML, no. 69
First or second remission, no. 42






Abbreviations: AML, acute myeloblastic leukemia; IPSS, International
Prognostic scoring system; RA, refractory anemia; RAEB, refractory
anemia with excess blasts; RCMD, refractory cytopenias with multi-
lineage dysplasia; RS, ringed sideroblast; t-AML, therapy-related AML;
WHO, World Health Organization.
Unrelated cord blood transplantation for myelodysplasia
M Robin et al
76
Leukemia
A total of 25 patients had therapy-related AML secondary
to the treatment of breast cancer (n¼ 9), lymphoma (n¼ 5),
acute lymphoblastic leukemia (n¼ 3) or other cancers (n¼ 8).
Maximum bone marrow blast counts before UCBT were
45% in 69 (92%) and 410% in 59 (78%) of the 75 evaluable
MDS patients. In all, 45 of the 49 assessable patients
with sAML received chemotherapy before transplantation.
At time of transplantation, 42 (61%) patients with sAML
were in first or second complete remission, 2 (3%) were
in third complete remission and 25 (36%) had progressive
disease.
Comorbidity score was available in 75 patients, and 42
patients had at least 1 comorbidity. Patients with comorbidities
were older (51 vs 39 years) and received a RIC (79 vs 36%) more
frequently. Conditioning regimens and GVHD prophylaxis are
shown in Table 2. MAC consisted of cyclophosphamide with
either total body irradiation (TBI) 46 Gy (n¼ 20) or busulfan
48 mg/kg (n¼ 12). RIC was based on fludarabine in all but
three patients combined with low-dose TBI (p2 Gy) in 33 (65%)
patients. A total of 49 (86%) MAC patients and 18 (35%)
RIC patients also received antithymoglobulin. In all, 11 (51%)
MAC patients and 41 (72%) RIC patients received GVHD
prophylaxis consisting of cyclosporine and mycophenolate.
UCBT characteristics are shown in Table 2.
Engraftment
The CI of neutrophil recovery was 78±4% at 60 days after
UCBT with a median time to achieve more than 0.5 109/l
neutrophils of 23 (6–51) days. In univariate analysis, neutrophil
recovery was decreased in patients (1) for whom time from
diagnosis to UCBT was 49.5 months (69±6% vs 87±5%;
P¼ 0.02), (2) who received o1.1 105 CD34þ cells/kg
(67±7% vs 86±6%; P¼ 0.002) and (3) who had 45% blasts
in the bone marrow at the time of UCBT (67±7% vs 86±5%;
P¼ 0.01). Patients who received RIC had similar engraftment
than those who received MAC. In multivariate analysis, bone
marrow blasts and number of CD34þ cells infused were
associated with increased neutrophil recovery (blasts o5%,
hazard ratio (HR): 1.91, 95% confidence interval (95% CI):
1.13–3.24, P¼ 0.016; CD34þ 41.1 105 cells per kg, HR:
2.02, 95% CI: 1.23–3.31, P¼ 0.005). Cumulative incidence
of platelet recovery was 50±5% at a median time of 50 days
(9–348).
Acute and chronic GVHD
The CI of grade II, III or IV aGVHD at day 100 was 26±4%.
Severe aGVHD (III and IV) occurred in 12 (11%) patients. The
CI of aGVHD at day 100 was 30±5% and 17±7% for single
and double CBT recipients, respectively (P¼ 0.16). Patient age
(age o43 years, CI: 26±6%; age 443 years, CI: 27±6%) and
type of conditioning regimen (RIC CI: 28±6%; MAC CI:
25±6%) were not statistically associated with aGVHD. In a
multivariate analysis, none of the factors studied influenced the
risk of aGVHD. Among patients who survived more than 100
days, chronic GVHD was observed in 19 patients; it was limited
in 9 (47%) and extensive in 10 (53%) patients. The CI of 2-year
chronic GVHD was 42±8%.
NRM and relapse
A 2-year CI of NRM was 49±5%. Results of the univariate
analysis are listed in Table 3. In multivariate analysis, RIC
(HR: 0.42; 95% CI: 0.24–0.76; P¼ 0.003) and shorter time from
diagnosis to UCBT (o9.5 months) were associated with lower
NRM (HR: 0.54; 95% CI: 0.31–0.94; P¼ 0 .03). Among patients
who received a MAC, those who received TBI had higher NRM
(84±8% vs 53±9%; P¼ 0.065). TBI did not influence NRM
in patients who received a RIC. Antithymoglobulin did not
increase NRM. CIs of NRM by the type of conditioning regimen
(RIC or MAC) are shown in Figure 1a.
A 2-year CI of relapse was 21±4%. In multivariate analysis,
risk factors associated with increased relapse incidence were
RIC (HR: 2.45; 95% CI: 1.01–5.9; P¼ 0.045) and high-risk
disease (HR: 3.96; 95% CI: 3.95–12.44; P¼ 0 .028).
OS and disease-free survival
The 2-year OS and DFS were 34±5% and 30±5% (Figure 1b).
Table 3 lists the univariate analysis for DFS. In multivariate
analysis, the only risk factor associated with better DFS
was lower disease risk at the time of UCBT (HR: 0.57; 95%
CI: 0.32–0.99; P¼ 0.047). There was a trend of improved
DFS when the number of CD34þ cells collected per kg was
higher than 1.1 105 (HR: 0.64; 95% CI: 0.39–1.06; P¼ 0.081).
In all, 20 patients died of relapse, infections were the
main cause of death in 24 patients and were associated with
GVHD in 9 or rejection in 4; hemorrhage was the cause of
death in 5, respiratory failure in 4, multiorgan failure in 3 and
other causes in 4 patients.




Median weight (range) 62 (39–97) 75 (45–108)
Conditioning regimen
Reduced intensity, no. (%) 29 (37) 22 (71)
Use of antithymoglobulin or
antilymphogloblulin, no. (%)
51 (66) 16 (52)
GVHD prophylaxis
Cyclosporine and mycophenolate 30 (39) 22 (71)
Cyclosporine and steroids 37 (48) 6 (19)
Other 10 (13) 3 (10)
Sex match, no. (%) 37 (48) 13 (42)
ABO blood group
ABO match, no. (%) 32 (42) 4 (13)
ABO minor mismatch, no. (%) 19 (25) 11 (36)
ABO major mismatch, no. (%) 23 (30) 15 (48)
Missing, no. (%) 3 (4) 1 (3)
HLA disparities (HLA-A and -B low resolution and -DRB1 allelic typing)
0, no. (%) 3 (4) 1 (3)
1, no. (%) 29 (37) 5 (16)
2, no. (%) 44 (57) 19 (61)
3, no. (%) 0 2 (6)
Median number of collected blood cells
Nucleated cells, 107/kg (range) 3.4 (1.9–7.3) 4.6 (2.9–7.6)
Missing 3 2
CD34+ cells,  105/kg (range) 1.4 (0.2–5) 2 (0.6–3.9)
Missing 5 5
Median number of infused cord
blood cells
Nucleated cells, 107/kg (range) 2.6 (0.7–6.8) 3.4 (1.6–5.8)
Missing 3 7
CD34+ cells,  105/kg (range) 1.2 (0.2–5.1) 1 (0.3–3.6)
Missing 5 7
Follow-up, months (range) 30.9 (7–75) 13.8 (2–40)
Abbreviations: GVHD, graft vs host disease; HLA, human leukocyte
antigen.
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Up to now, studies reporting results of UCBT for MDS patients
have been scarce.17,26 Here, we report an International survey
of patients who received UCBT for MDS or sAML. DFS was
30%, which appears to be comparable to DFS after HSCT using
other types of donors in large multicentric studies in high-risk
MDS patients.16,27 In our study, early and late outcomes were







Secondary leukemia 45±6 31±6
Myelodysplasia 57±9 0.12 28±8 0.24
Blasts o5% at the time of CBT
Yes 45±7 34±7
No 49±8 0.44 26±8 0.23
Disease risk group at the time of CBT
High risk 47±6 23±6
Low risk 48±9 0.75 46±9 0.05
Median age
o43 years 51±7 30±6
X43 years 48±8 0.65 31±6 0.97
Year of transplantation
Before 2006 52±7 29±6
2006 and after 47±8 0.46 28±7 0.31
Conditioning regimen
Myeloablative 62±7 24±6
Reduced intensity 34±7 0.009 37±7 0.27
GVHD prophylaxis
Cyclosporine + steroid 61±8 24±7
Cyclosporine + mycophenolate 34±7 42±8
Other 60±14 0.0026 13±9 0.10
Serotherapy
No 34±9 38±9
Yes 57±6 0.12 26±4 0.75
Number of cord blood units
Single cord blood 52±6 33±6
Double cord blood 42±10 0.46 22±9 0.44
Time from diagnosis to transplantation
o9.5 months 34±7 42±6
9.5 months or more 26±6 0.065 56±7 0.09
HLA disparities
0 or 1 antigen mismatch 50±9 30±8
2 or more antigens mismatch 47±7 0.99 31±6 0.76
Irradiation
Yes 51±7 28±7
No 47±7 0.96 32±7 0.82
CMV serology for recipient
Positive 48±6 33±6
Negative 49±10 0.52 28±8 0.86
Nucleated cell dose collected
o3.6 107/kg 54±7 30±7
X3.6 107/kg 43±7 0.44 31±7 0.94
CD34+ cell dose collecteda
o1.1 105/kg 62±9 19±7
41.1 105/kg 42±6 0.11 35±6 0.08
aMissing data for 10 patients.
Abbreviations: CBT, cord blood transplantation; CMV, cytomegalovirus; GVHD, graft vs host disease; HLA, human leukocyte antigen.
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associated with the number of CD34 cells infused, type of
conditioning regimen, the time from diagnosis to transplantation
and, importantly, disease status at UCBT.
The advantage of our study is the relatively high number of
patients included and the possibility to perform a risk factor
analysis. However, as UCBT is not frequently performed in MDS
patients, we analyzed a relatively heterogeneous group of
patients receiving single or double UCBT following RIC or MAC
performed in 47 centers. Currently, UCBT for MDS represents
the minority of UCBT indications and consequently, a lot of
participating transplant centers performing few transplants for
MDS were included. Of note, MDS patients in this study were
rigidly selected: they were relatively young, with relatively low
weight and an aggressive disease, including transformation
into acute leukemia in more than half of the patients, and
in sufficiently good general health to undergo allogeneic
transplantation.
Non-engraftment and delayed immune recovery are possible
risks that currently limit indications for performing UCBT.
A recent study has shown that neutrophil engraftment was
decreased in children with MDS as compared with children with
acute leukemia receiving UCBT.28 In our study, the CI of
neutrophil engraftment was 78% and it was associated with
CD34þ cell dose and blast count at the time of UCBT. A
CD34þ cell dose higher than 1.1 106/kg was the threshold
found in our study associated with engraftment, in concordance
with previous studies.29,30 One could argue that the use of
double cord blood transplantation could increase the probability
of engraftment; however, this was not observed in our study. In
fact, CD34 cell dose in double UCBT was equivalent to those in
single UCBT, thus reflecting that double UCB grafts were used to
overcome the lower cell dose contained in a single unit.
As expected, after UCBT, the CI of aGVHD was low.
In contrast to a recent report,31 patients who received double
UCBT were not at greater risk for developing GVHD but these
results should be interpreted with caution as the first double
UCBT in this study was performed in 2001 and transplantation
practices may have changed over time. For example, GVHD
prophylaxis consisted of cyclosporine plus steroids in the
majority of single UCBT recipients and cyclosporine plus
mycophenolate in the majority of double UCBT recipients.
Antithymoglobulin use before transplantation had no impact on
GVHD occurrence (data not shown).
NRM remains important in UCBT and the most frequent
cause of death is infection. Indeed, immune reconstitution is
slower than in matched related donor transplanted patients, and
infections are important complications.32 In our study, time
elapsed from diagnosis to UCBT and MAC increase were
significant independent risk factors for NRM. A long delay
before transplantation is often associated with multiple treat-
ments and transfusions, increasing the risk of organ failure,
infection, iron overload or more advanced disease. Disease
duration before transplantation or iron overload has been
regularly found to increase NRM and sometimes decrease
survival in bone marrow or peripheral blood transplant
recipients.33–36 Our study confirmed that RIC before UCBT is
associated with a reduction in NRM, as observed in unrelated
HSCT recipients.36
Despite poorer general conditions and high-risk MDS,
patients who received RIC had decreased NRM and a trend
toward better DFS. The increased risk of relapse observed after
RIC did not translate into poorer survival in our study despite a
high proportion of patients with advanced disease. Furthermore,
high-risk patients who received MAC had no survival advantage
compared with high-risk patients who received RIC (data not
shown). High-dose TBI appeared to result in particularly high
NRM.
The most important risk factor for DFS was disease risk at the
time of transplantation. These results raise the issue of pre-
transplantation treatment to reduce disease tumor burden
without postponing transplantation, which increases NRM. No
randomized study exists to assess the role of chemotherapy
before transplantation. New drugs such as demethylating agents
are now widely used in MDS patients but very few data are
currently available to analyze their impact before allogeneic
transplantation.37 Our results indicate that although it is better to
transplant MDS patients with less active disease, patients
who transform into secondary AML may still benefit from UCBT
if they have achieved remission before transplantation. The
Markov decision model in MDS patients with an HLA-identical
sibling donor has shown that patients had a life expectancy
advantage if they were transplanted before the AML occur-
rence,38 but no such data exist for transplantation from an
unrelated donor.
Our study shows that UCBT can be used in high-risk MDS



































Figure 1 (a) Cumulative incidence of non-relapse mortality by
conditioning regimen. Black line represents cumulative incidence of
non-relapse mortality after MAC and dotted line represents cumulative
incidence of non-relapse mortality after reduced intensity conditioning
regimen. (b) Disease-free survival estimation by risk disease group.
Black line represents disease-free survival in patients with lower risk
disease (AML in remission, MDS with o5% blasts). Dotted line
represents disease-free survival in patients with higher risk disease.
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a mismatched unrelated donor is better or worse than UCBT in
MDS adults, but HSCT remains the only curative treatment
in advanced MDS patients. In acute or chronic leukemia,
transplantation from an HLA-matched or one HLA allele-
mismatched unrelated donor is associated with 5–10 and
10–15% lower survival rates, respectively, when compared
with transplantation from an HLA-matched sibling donor,
despite high resolution HLA typing.39,40 With respect to the
source of unrelated stem cells, HLA-mismatched bone marrow
or cord blood transplants have been shown to give similar
outcome in adults with acute leukemia.2 Furthermore, outcomes
with cord blood transplantation have been reported to be similar
to that of HLA-matched bone marrow by Rocha et al.3 but this
was not confirmed by Laughlin et al.2 In patients with MDS, DFS
appears to be similar to that achieved using other unrelated
hematopoietic stem cell sources, but comparative studies are
required to better determine the role of UCBT for this group of
patients.
Conflict of interest
The authors declare no conflict of interest.
References
1 Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C
et al. Comparison of outcomes of unrelated bone marrow and
umbilical cord blood transplants in children with acute leukemia.
Blood 2001; 97: 2962–2971.
2 Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ,
Champlin RE et al. Outcomes after transplantation of cord blood or
bone marrow from unrelated donors in adults with leukemia.
N Engl J Med 2004; 351: 2265–2275.
3 Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A
et al. Transplants of umbilical-cord blood or bone marrow from
unrelated donors in adults with acute leukemia. N Engl J Med
2004; 351: 2276–2285.
4 Gluckman E, Rocha V, Arcese W, Michel G, Sanz G, Chan KW
et al. Factors associated with outcomes of unrelated cord blood
transplant: guidelines for donor choice. Exp Hematol 2004; 32:
397–407.
5 Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB,
Miller JS et al. Transplantation of 2 partially HLA-matched
umbilical cord blood units to enhance engraftment in adults with
hematologic malignancy. Blood 2005; 105: 1343–1347.
6 Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS,
Blazar BR et al. Umbilical cord blood transplantation after
nonmyeloablative conditioning: impact on transplantation
outcomes in 110 adults with hematologic disease. Blood 2007;
110: 3064–3070.
7 de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P,
Hayat M et al. Intensive chemotherapy for poor prognosis
myelodysplasia (MDS) and secondary acute myeloid leukemia
(sAML) following MDS of more than 6 months duration. A pilot
study by the Leukemia Cooperative Group of the European
Organisation for Research and Treatment in Cancer (EORTC-
LCG). Leukemia 1995; 9: 1805–1811.
8 Ruutu T, Hanninen A, Jarventie G, Koistinen P, Koivunen E,
Katka K et al. Intensive chemotherapy of poor prognosis myelodys-
plastic syndromes (MDS) and acute myeloid leukemia following
MDS with idarubicin and cytarabine. Leuk Res 1997; 21: 133–138.
9 Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B,
Rassam SM et al. Fludarabine, cytarabine, G-CSF and idarubicin
(FLAG-IDA) for the treatment of poor-risk myelodysplastic
syndromes and acute myeloid leukaemia. Br J Haematol 1997;
99: 939–944.
10 Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA,
Garcia-Manero G et al. Multicenter study of decitabine adminis-
tered daily for 5 days every 4 weeks to adults with myelodysplastic
syndromes: the alternative dosing for outpatient treatment
(ADOPT) trial. J Clin Oncol 2009; 27: 3842–3848.
11 Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD,
Cohn AL et al. Hematologic response to three alternative dosing
schedules of azacitidine in patients with myelodysplastic
syndromes. J Clin Oncol 2009; 27: 1850–1856.
12 Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C,
Giagounidis A et al. Efficacy of azacitidine compared with that of
conventional care regimens in the treatment of higher-risk
myelodysplastic syndromes: a randomised, open-label, phase III
study. Lancet Oncol 2009; 10: 223–232.
13 Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT,
Beach CL et al. Further analysis of trials with azacitidine in patients
with myelodysplastic syndrome: studies 8421, 8921, and 9221
by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24:
3895–3903.
14 de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C
et al. Intensive chemotherapy followed by allogeneic or auto-
logous stem cell transplantation for patients with myelodysplastic
syndromes (MDSs) and acute myeloid leukemia following MDS.
Blood 2001; 98: 2326–2331.
15 Sierra J, Perez WS, Rozman C, Carreras E, Klein JP, Rizzo JD et al.
Bone marrow transplantation from HLA-identical siblings as
treatment for myelodysplasia. Blood 2002; 100: 1997–2004.
16 Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R,
Dharan B et al. Unrelated donor marrow transplantation for
myelodysplastic syndromes: outcome analysis in 510 transplants
facilitated by the National Marrow Donor Program. Blood 2002;
99: 1943–1951.
17 Arcese W, Rocha V, Labopin M, Sanz G, Iori AP, de Lima M et al.
Unrelated cord blood transplants in adults with hematologic
malignancies. Haematologica 2006; 91: 223–230.
18 Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C,
Harrison G et al. The importance of diagnostic cytogenetics on
outcome in AML: analysis of 1612 patients entered into the MRC
AML 10 trial. The Medical Research Council Adult and Children’s
Leukaemia Working Parties. Blood 1998; 92: 2322–2333.
19 Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al.
International scoring system for evaluating prognosis in myelo-
dysplastic syndromes. Blood 1997; 89: 2079–2088.
20 Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney
DG et al. Hematopoietic cell transplantation (HCT)-specific
comorbidity index: a new tool for risk assessment before
allogeneic HCT. Blood 2005; 106: 2912–2919.
21 Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA
et al. Clinical manifestations of graft-versus-host disease in
human recipients of marrow from HLA-matched sibling donors.
Transplantation 1974; 18: 295–304.
22 Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE,
Sale GE et al. Chronic graft-versus-host syndrome in man. A long-
term clinicopathologic study of 20 Seattle patients. Am J Med
1980; 69: 204–217.
23 Kaplan EM, P. Nonparametral estimation from incomplete
observations. J Am Stat Assoc 1958; 53: 457–481.
24 Fine JG, RJ. A proportional hazard model for the subdistribution of
a competing risk. J Am Stat Assoc 1999; 94: 496–509.
25 Cox D. Regression models and life tables. J R Stat Soc 1972; 34:
187–202.
26 Ooi J, Iseki T, Takahashi S, Tomonari A, Ishii K, Takasugi K et al.
Unrelated cord blood transplantation for adult patients with
advanced myelodysplastic syndrome. Blood 2003; 101: 4711–4713.
27 de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G,
Jacobsen N et al. Haematopoietic stem cell transplantation for
patients with myelo-dysplastic syndromes and secondary acute
myeloid leukaemias: a report on behalf of the Chronic Leukaemia
Working Party of the European Group for Blood and Marrow
Transplantation (EBMT). Br J Haematol 2000; 110: 620–630.
28 Moreno Madureira A, Eapen M, Locatelli F, Teira P, Zhang MJ,
Davies SM et al. Analysis of risk factors influencing outcome in
children with myelodysplastic syndrome after unrelated cord
blood transplantation: on behalf of the European Working Group
of Myelodysplastic Syndrome in Childhood, Center for Interna-
tional Blood and Marrow Transplant Research and Eurocord-
European Group for Blood and Marrow Transplantation.
Submitted.
Unrelated cord blood transplantation for myelodysplasia
M Robin et al
80
Leukemia
29 Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA,
Wagner JE et al. Hematopoietic engraftment and survival in adult
recipients of umbilical-cord blood from unrelated donors. N Engl J
Med 2001; 344: 1815–1822.
30 Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud
M et al. Analysis of risk factors for outcomes after unrelated cord
blood transplantation in adults with lymphoid malignancies: a
study by the Eurocord-Netcord and lymphoma working party
of the European group for blood and marrow transplantation.
J Clin Oncol 2009; 27: 256–263.
31 MacMillan ML, Weisdorf DJ, Brunstein CG, Cao Q, DeFor TE,
Verneris MR et al. Acute graft-versus-host disease after unrelated
donor umbilical cord blood transplantation: analysis of risk factors.
Blood 2009; 113: 2410–2415.
32 Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S,
McNiece I et al. Delayed immune reconstitution after cord blood
transplantation is characterized by impaired thymopoiesis and late
memory T-cell skewing. Blood 2007; 110: 4543–4551.
33 Altes A, Remacha AF, Sureda A, Martino R, Briones J, Canals C
et al. Iron overload might increase transplant-related mortality in
haematopoietic stem cell transplantation. Bone Marrow Transplant
2002; 29: 987–989.
34 del Canizo MC, Martinez C, Conde E, Vallejo C, Brunet S, Sanz G
et al. Peripheral blood is safer than bone marrow as a source of
hematopoietic progenitors in patients with myelodysplastic syn-
dromes who receive an allogeneic transplantation. Results from
the Spanish registry. Bone Marrow Transplant 2003; 32: 987–992.
35 Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al.
Prognostic impact of elevated pretransplantation serum ferritin in
patients undergoing myeloablative stem cell transplantation. Blood
2007; 109: 4586–4588.
36 Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J
et al. Retrospective comparison of reduced-intensity conditioning
and conventional high-dose conditioning for allogeneic hemato-
poietic stem cell transplantation using HLA-identical sibling
donors in myelodysplastic syndromes. Blood 2006; 108: 836–846.
37 De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P,
Giralt S et al. Feasibility of allo-SCT after hypomethylating therapy
with decitabine for myelodysplastic syndrome. Bone Marrow
Transplant 2009; 43: 839–843.
38 Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C
et al. A decision analysis of allogeneic bone marrow transplanta-
tion for the myelodysplastic syndromes: delayed transplantation
for low-risk myelodysplasia is associated with improved outcome.
Blood 2004; 104: 579–585.
39 Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP,
Hurley CK et al. HLA-identical sibling compared with 8/8 matched
and mismatched unrelated donor bone marrow transplant for
chronic phase chronic myeloid leukemia. J Clin Oncol 2009; 27:
1644–1652.
40 Ringden O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D
et al. The graft-versus-leukemia effect using matched unrelated
donors is not superior to HLA-identical siblings for hematopoietic
stem cell transplantation. Blood 2009; 113: 3110–3118.
Unrelated cord blood transplantation for myelodysplasia
M Robin et al
81
Leukemia
